FCP
TMO icon

Fidelis Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History

Fidelis Capital Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Buy
5,740
+56
+1% +$26.9K 0.17% 106
2026
Q1 		$2.79M Sell
5,684
-408
-7% -$221K 0.2% 97
2025
Q4 		$3.53M Buy
6,092
+570
+10% +$322K 0.26% 81
2025
Q3 		$2.68M Buy
5,522
+1,448
+36% +$674K 0.21% 90
2025
Q2 		$1.83M Sell
4,074
-197
-5% -$82.4K 0.17% 108
2025
Q1 		$1.81M Buy
4,271
+628
+17% +$340K 0.19% 95
2024
Q4 		$2.16M Buy
3,643
+472
+15% +$260K 0.22% 85
2024
Q3 		$1.83M Buy
3,171
+25
+0.8% +$14.8K 0.22% 85
2024
Q2 		$1.85M Sell
3,146
-195
-6% -$112K 0.26% 73
2024
Q1 		$1.94M Buy
3,341
+202
+6% +$113K 0.29% 68
2023
Q4 		$1.67M Buy
3,139
+256
+9% +$124K 0.37% 58
2023
Q3 		$1.46M Buy
2,883
+257
+10% +$137K 0.5% 43
2023
Q2 		$1.37M Buy
2,626
+133
+5% +$71.8K 0.5% 50
2023
Q1 		$1.36M Buy
2,493
+1,158
+87% +$653K 0.58% 45
2022
Q4 		$729K Buy
+1,335
New +$707K 0.86% 32

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelis Capital Partners's TMO Position: Q2 2026 in Review

Fidelis Capital Partners increased its Thermo Fisher Scientific (TMO) stake by 0.99% in Q2 2026, buying an estimated $26.9K and bringing the position to 5,740 shares worth $2.88M. The position accounts for 0.17% of the portfolio, ranked #106.

Fidelis Capital Partners first reported a position in TMO in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.53M in Q4 2025. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Fidelis Capital Partners held 5,740 shares of Thermo Fisher Scientific worth $2.88M as of Q2 2026.
  • Fidelis Capital Partners bought 56 Thermo Fisher Scientific shares in Q2 2026, an estimated $26.9K.
  • Thermo Fisher Scientific made up 0.17% of Fidelis Capital Partners's portfolio in Q2 2026, its #106 holding.
  • Fidelis Capital Partners first reported a position in Thermo Fisher Scientific in Q4 2022 and has held it in 15 quarters since.
  • Fidelis Capital Partners's Thermo Fisher Scientific position peaked at $3.53M in Q4 2025.
  • 2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.